Results 121 to 130 of about 231,116 (154)

Challenges of neoadjuvant immunotherapy in mismatch repair-deficient/microsatellite-unstable localized colon cancer patients. [PDF]

ESMO Open
Karoui M, Mariani A, Taieb J.
europepmc   +1 more source

Spatial architecture contributes to failure of bulk biomarker-guided neoadjuvant immunotherapy selection in bladder cancer: The DUTRENEO study. [PDF]

Cell Rep Med
Grande E, Sibai M, Grases D, Andrada E, Reig O, Escobosa M, Azueta A, Castellano D, Puente J, Martínez de Villarreal J, Font A, Alonso-Gordoa T, Benítez R, Moreno-Oya A, Álvarez-Maestro M, Burgos J, Climent MA, Domínguez M, Galván P, Galante I, García JF, Perez E, García Del Muro X, Guerrero-Ramos F, Marqués M, Maroto P, Paramio JM, Pinto A, Prat A, Malats N, Durán I, Porta-Pardo E, Real FX.   +32 more
europepmc   +1 more source

Conversion TORS after neoadjuvant immunotherapy for advanced BOT-SCC: a retrospective study. [PDF]

Front Oncol
Lin Q, Zhang Y, Sun J, Hui X, Ren Y, Song Z, Wu Z, Cai B, Feng L, Zhang H, Wang F, Xi Q.   +11 more
europepmc   +1 more source

The Efficacy and Safety of Neoadjuvant Immunotherapy in Pan-Squamous Cell Carcinomas: A Meta-Analysis of Esophageal, Head and Neck, Cervical, Lung, Cutaneous, and Oral Squamous Cell Carcinomas. [PDF]

J Clin Med
Fu X, Xu S, Wang M.
europepmc   +1 more source

Real-World Outcomes for Patients with Clinically Node-Positive Melanoma Undergoing Neoadjuvant Immunotherapy and Nodal Dissection. [PDF]

Ann Surg Oncol
Herb J, Bassett RL, Torres-Cabala CA, Prieto VG, Patel SP, Holder AM, Fisher SB, Lucci A, Wargo J, Amaria RN, Davies MA, Glitza Oliva IC, Tawbi HA, McQuade J, Ikeguchi AP, Wong MK, Diab AK, Gershenwald JE, Ross MI, Weiser R.   +19 more
europepmc   +1 more source

Neoadjuvant immunotherapy in mismatch-repair-proficient colon cancers. [PDF]

Nature
Tan PB, Verschoor YL, van den Berg JG, Balduzzi S, Kok NFM, Ijsselsteijn ME, Moore K, Jurdi A, Tin A, Kaptein P, van Leerdam ME, Haanen JBAG, Voest EE, de Miranda NFCC, Schumacher TN, Wessels LFA, Chalabi M.   +16 more
europepmc   +1 more source

Top advances of the year: Neoadjuvant immunotherapy in melanoma. [PDF]

Cancer
Chen MF, Postow MA.
europepmc   +1 more source

Neoadjuvant immunotherapy combined with HER2-targeted antibody-drug conjugate in bladder urothelial carcinoma: a case report. [PDF]

BMC Urol
Guo Z, Wang G.
europepmc   +1 more source

Dynamic systemic immune-inflammation index predicts survival after neoadjuvant immunotherapy in gastric cancer: A multicenter study. [PDF]

iScience
Zheng HL, Shen LL, Lv CB, Lin J, Xu BB, Xue Z, Lu J, Zheng ZW, Huang CM, Wang JB, Zheng CH.   +10 more
europepmc   +1 more source

Deep learning models based on CT predict prognosis in patients with locally advanced esophageal squamous cell carcinoma who received neoadjuvant immunotherapy and chemotherapy. [PDF]

Front Immunol
Zhao J, Yuan Z, Shi H, Li Y, Li C, Zhang R, Liu C.   +6 more
europepmc   +1 more source